Ovarian Cancer Survival: How Peri-Operative Beta Blockers Impact Outcomes
"A closer look at the surprising effects of selective and nonselective beta-blockers on ovarian cancer patients' survival and recurrence rates."
Ovarian cancer remains a significant health challenge for women, necessitating continuous research into treatment strategies and factors influencing survival rates. Recent preclinical studies have explored the role of adrenergic agonists in promoting tumor growth and invasiveness in ovarian cancer, specifically through the beta-2 adrenergic receptor. These findings have prompted investigations into whether beta-blockers, commonly prescribed medications that counteract these adrenergic effects, could impact epithelial ovarian cancer (EOC) survival.
Beta-blockers are primarily used to manage conditions such as hypertension, anxiety, and heart conditions by blocking the effects of adrenaline and noradrenaline. The use of these medications in the context of cancer treatment has been a topic of interest due to their potential to influence cancer progression and outcomes. However, clinical results have been conflicting, leading researchers to delve deeper into understanding the nuances of beta-blocker usage and its effects on cancer patients.
To address these uncertainties, a study was conducted to examine the association between peri-operative beta-blockade and clinical outcomes in EOC patients. The study retrospectively reviewed patient data to assess the impact of beta-blocker use on overall survival (OS) and progression-free survival (PFS), considering the timing of beta-blocker administration relative to surgery. The results of this research shed light on the complex interplay between beta-blockers and ovarian cancer progression, providing valuable insights for clinicians and patients alike.
Study Design and Interpretation
A 2020 retrospective cohort study reviewed charts of women with stage IIIC or IV epithelial ovarian cancer who underwent primary or interval cytoreduction. It identified beta-blocker use at the time of cytoreduction as the exposure and progression-free survival (PFS) and overall survival (OS) as outcomes. A separate review notes that post-diagnostic beta-blocker use can be associated with factors including age at diagnosis, cancer stage, comorbidities, chemotherapy administration, and use of other drugs, which complicates interpretation of observational associations.
A Repurposing Hypothesis
A 2015 article considered whether beta-blockers might have therapeutic potential in patients with cancer. It pointed to beta-blockers’ established use for managing hypertension and proposed that these widely used medications might affect cancer through changes in biological processes. The article presented this as a therapeutic possibility, rather than an established cancer treatment.
Selective vs. Nonselective: Understanding the Impact of Beta-Blocker Type
The study utilized a cox survival model to evaluate the outcomes of women who took selective beta-blockers (SBBs) during the peri-operative period. The results indicated a concerning trend: women who used SBBs were four times more likely to die compared to non-users, as indicated by an adjusted hazard ratio (HR) of 5.82 (95% CI 1.17-28.91, p=0.031). This finding suggests that SBB usage around the time of surgery may have a detrimental effect on overall survival.
- Selective Beta-Blockers (SBBs): Usage during the peri-operative period was associated with a fourfold increase in the likelihood of death compared to non-users.
- Nonselective Beta-Blockers (NSBBs): No significant difference in progression-free survival was observed between users and non-users.
- Recurrence of Disease: SBB users were four times more likely to experience disease recurrence compared to non-users.
Recent Evidence on Survival
A study based on a large cohort of women who underwent epithelial ovarian cancer surgery and nationwide population-based registries evaluated beta-blocker use in relation to survival after diagnosis. A separate study published December 1, 2024, examined whether co-medication with metformin, a statin, or a beta blocker was associated with survival in patients with primary ovarian cancer. A 2021 systematic review and meta-analysis covered 11 cohort studies with 20,274 patients. A broader 2025 systematic review and meta-analysis assessed beta-blocker use and survival outcomes across cancer patients, noting that clinical findings have been inconsistent.
Inconsistent Findings and Bias
Clinical studies of beta-blockers and ovarian cancer survival have produced inconsistent results, and observational findings may be affected by methodological limitations. One report notes that two earlier studies reporting improved survival among beta-blocker users were likely biased by including immortal person-time. Another source likewise cautions that observational results remain inconsistent and may be impaired by methodological limitations. These concerns limit how confidently survival benefits can be inferred from the available observational evidence.
Clinical Evidence Versus Experimental Promise
Experimental models suggest that beta-blockers, a commonly used antihypertensive medication, may improve survival in ovarian cancer patients. However, clinical study results have been mixed. The study described in this source evaluated associations between ovarian cancer survival and pre-diagnostic antihypertensive medication use, with 950 participants noted for the pre-diagnostic analysis. This contrast underscores that experimental promise and clinical evidence do not yet point uniformly in the same direction.
Future Directions and Clinical Implications
The study's findings suggest that peri-operative SBB use is associated with poorer overall survival, while any SBB use is linked to poorer progression-free survival in patients with EOC. While preclinical studies might hint at survival benefits, the current clinical data indicates a potential harm from SBB use, underscoring the necessity for further investigation. Future research should aim to clarify the underlying mechanisms and explore alternative strategies to improve outcomes for women with ovarian cancer.
Interpreting Peri-Operative Evidence
A retrospective cohort study reviewed charts of women with stage IIIC or IV epithelial ovarian cancer who underwent primary or interval cytoreduction. It defined beta-blocker exposure by use identified at the time of cytoreduction and examined progression-free survival and overall survival. This study design directly addresses peri-operative use in this defined patient group, while its retrospective nature means it reports an association-focused analysis rather than establishing a treatment effect.
Research Directions for Beta-Blocker Combinations
A 2024 review explores how non-selective beta blockers (NSBBs) and selective beta blockers (SBBs) may contribute to combination cancer treatment and presents future research directions. The supplied source does not establish that either class improves ovarian cancer survival, so their role remains a research question. A separate ovarian cancer review describes substantial molecular heterogeneity and diagnostic challenges, framing the disease as a field where integrated understanding of emerging mechanisms remains important.